4 replies to this topic

[gerry]

http://www.haematolo...ntent/100/1/e39

[rcase13]

This is the first I have heard of Radotinib. Too bad the article wasn't written in southern English! I understood about half of it! They need to have a dumbed down translation for southerns like me!

[Trey]

Still early in clinical trials.  Results are good but a rather high rate of drug interruptions and patients quitting the drug before 12 months:

71.4% of the patients had a dose interruption

42.9% of the patients discontinued treatment before 12 months

 

But more drug options is always good.  Maybe it will have a niche role.  Approval may be a couple years away.  This drug is being developed by a Korean company, so it may be available in Asia earlier.

[gerry]

In CML: Radotinib as Frontline Therapy; Ponatinib Promising for T315I Patients

 

ORLANDO, Florida—Two tyrosine kinase inhibitors (TKIs)—one a new drug from Korea, the other designed to target hard-to-treat T315I mutations—show promise as potential treatments for chronic myeloid leukemia (CML) to replace imatinib or allogeneic stem cell transplant (SCT) in selected patients, according to two new studies presented here at the American Society of Hematology Annual Meeting.

http://journals.lww....natinib.13.aspx

[survenant]

See also   Supect (Radotinib)